Objectives: Routinely used performance status scales, assessing patients' suitability for cancer treatment, have limited ability to account for multimorbidity, frailty and cognition. The Clinical Frailty Scale (CFS) is a suggested alternative, but research detailing its use in oncology is limited. This study aims to evaluate if CFS is associated with prognosis and care needs on discharge in oncology inpatients.Methods: We evaluated a large, single-centre cohort study in this research. CFS was recorded for adult inpatients at a Regional Cancer Centre. The associations between CFS, age, tumour type, discharge destination and care requirements and survival were evaluated.Results and Conclusions: A total of 676 patients were included in the study. Levels of frailty were high (Median CFS 6, 81.8% scored ≥5) and CFS correlated with performance status (R = 0.13: P = 0.047). Patients who were frail (CFS ≥ 5) were less likely to be discharged home (62.9%) compared with those who were not classed as frail (86.1%) (OR 3.6 [95%CI 2.1 to 6.3]: P < 0.001). Higher CFS was significantly associated with poorer prognosis in all ages. Solid organ malignancy (hazard ratio [HR] 2.60 [95%CI 2.05-3.32]) and CFS ; P < 0.001) were independently associated with poorer survival. This study demonstrated that CFS may help predict prognosis in adult oncology inpatients of any age. This may aid informed shared decision-making in this setting. Future work should establish if routine CFS measurement can aid the appropriate prescription of systemic therapy and enable early conversations about discharge planning.

No abstract

e14522 Background: Corticosteroids are commonly used in neuro-oncology both in the perioperative setting and with chemotherapy and radiotherapy to manage cancer and treatment-associated cerebral oedema and neurological deficits. Corticosteroids are associated with significant morbidity. We sought to identify primary brain tumour patients affected by steroid complications within our centre, the repercussions on their treatment and whether these consequences are avoidable. Methods: This retrospective study curated the last 50 primary brain tumour patients treated radically and therefore at risk of long term steroid use between November 2018 and August 2019. Patient demographics, tumour and treatment type, as well as diabetic and steroid history were collected. A second cohort of primary brain patients undergoing radical radiotherapy were recruited between November 2019 and January 2020. HbA1c blood tests were performed and NICE guidelines used for HbA1c diagnostic criteria with referral to diabetic services and outcomes recorded. Results: Tumour types ranged from Glioblastoma (36%), meningioma (32%), oligodendroglioma (16%), astrocytoma (14%) and hemangioblastoma (2%). 12 (24%) had a known diabetes diagnosis. Forty-two (84%) had an operation (biopsy (30%), partial (18%) or full debulking (16%). 82% of patients were exposed to dexamethasone at some point during their neurosurgical or oncological treatment. Initial doses varied but 36% were placed on 8mg twice daily. Steroid-induced hyperglycaemia occurred in 8 (16% of the cohort) with admission to hospital as a consequence in half of these cases, of whom two were newly diagnosed diabetes patients. HbA1c testing prior to or during treatment occurred in 16 (32%) patients. In the second cohort, All 15 patients (100%) had HbA1c testing with 5 (33%) patients diagnosed with diabetes or at risk of diabetes. Diabetic team advice was sought and recommended blood glucose testing in all these patients with oral hypoglycaemic and/or insulin dose modification in 3 (60%). There were no hyperglycaemic recordings or subsequent admissions to hospital in this cohort. Conclusions: We therefore recommend HbA1c testing and early diabetic team involvement in all primary brain tumour patients receiving radical radiotherapy.

No abstract

No abstract